Latest Regulatory News

Verbrec Limited is streamlining its business by selling its Competency Training division for $11.5 million and acquiring Alliance Automation for $5.5 million, significantly boosting its digital and automation capabilities.

Santana Minerals has been granted a crucial 25-year mining permit for its Bendigo-Ophir Gold Project in New Zealand, paving the way for construction and gold production pending environmental approvals.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

RAS Technology Holdings has landed a significant contract to provide racing data and managed trading services for LeoVegas Group’s UK brands, including BetMGM UK, marking a strategic expansion into regulated markets.

Peel Mining Limited reveals a robust high-grade resource base and ongoing exploration in the Cobar Basin, positioning itself for growth amid a dynamic regional mining landscape.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

Energy Transition Minerals has appointed two former Danish diplomats to its Advisory Board, aiming to strengthen its rare earths project in Greenland amid ongoing legal challenges.

Artrya secures participation from Mass General Brigham, a leading U.S. cardiovascular research center, in its pivotal SAPPHIRE Study launching in early 2026. This collaboration aims to validate Artrya’s AI-powered Salix platform for earlier and more effective coronary artery disease detection.

Tryptamine Therapeutics has raised $6.1 million to fast-track clinical development of its IV-infused psilocin drug TRP-8803, targeting binge eating disorder and other neuropsychiatric conditions.

Kinetiko Energy has secured the first tranche of funding from FFS Refiners to accelerate development of a pilot LNG gas plant at Brakfontein, marking a key step in its multi-phase Project Alpha.

Imagion Biosystems reports encouraging findings from its Wayne State University collaboration, supporting a lower dose for its MagSense® HER2 imaging agent ahead of a planned FDA IND submission in Q4 2025.